Tools   Select Another Resource Report Type

http://www.michr.umich.edu/services/biorepository

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 24,2025. In 2009, the Medical School and the Michigan Institute for Clinical & Health Research (MICHR) unveiled a new biorepository for U-M researchers in need of a controlled storage environment for biological samples. MICHR is pleased to be able to add to its many services for the research community a centralized biological repository for controlled storage of biological samples, and related services (including DNA, RNA, and other downstream preparation) within the U-M campus. The biorepository, located in the CAP/CLIA-certified Michigan Center for Translational Pathology (MCTP) laboratory at the U-M Traverwood facility on Huron Parkway, will store biologic material, including blood and urine. Sample accessioning and tracking will be accomplished using the caTISSUE suite of programs, and samples will be processed and stored in compliance with CAP/CLIA guidelines. Initially, all samples will be used only with the authorization of the individual investigator who directed the project under which the samples were obtained. Samples will be used in accordance with the relevant informed consent. Long-term plans include federating the database in order to facilitate sharing of data and samples between research teams.

Proper citation: University of Michigan Biorepository (RRID:SCR_004643) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/research/ki-biobank

KI Biobank is an accredited core facility offering sample collection services. KI Biobank is located at the Department of Medical Epidemiology and Biostatistics. KI Biobank offer infrastructure for pre analytical sample handling and provide researchers guidance on how samples should be taken and labeled. The processes comprise registration, handling, storage and distribution of samples. KI Biobank also offers DNA-extraction from blood and saliva. In order to insure complete traceability on samples and belonging information all processes are controlled by a Laboratory Information Management System (LIMS). For every new study a contract is established describing the study and the disposition rights. We also help in writing Biobank agreements including multicenteravtal and Material Transfer Agreement. KI Biobank is, according to the Biobank law, responsible for all sample collections handled within the core facility and those that are stored on the departments on KI campus. Clinical sample collections are handled by the Biobank units at the respective hospitals within the Stockholm County Council. Besides the samples that are stored centrally at KI Biobank, KI Biobank is also the administrative biobank for research sample collections at Karolinska Institutet that are stored and administrated at the departments. All research sample collections must be reported to KI Biobank. The following types of sample collections are registered in the biobank; sample collections taken within the regular health care that has been transferred to Karolinska Institutet with an agreement of transfer, samples taken from healthy individuals or other persons out of the regular health care and samples that have been taken abroad.

Proper citation: Karolisnka Biobank (RRID:SCR_004355) Copy   

•   Source: SciCrunch Registry

http://www.wmt.com

An ISO 9001 certified designer, manufacturing and distributing orthopedic implants and instrumentation worldwide for over 50 years. Wright''s product offerings include large joint implants for the hip and knee; extremity implants for the shoulder, elbow, hand, wrist and foot; and both synthetic and tissue-based bone graft substitute materials. Since its inception, Wright has introduced a number of products that represent new standards in orthopedic technology. From new material technologies to advanced products and instrumentation, Wright is committed to finding solutions to the challenges that face today''s orthopedic professionals.

Proper citation: Wright Medical Technology, Inc. (RRID:SCR_004195) Copy   

•   Source: SciCrunch Registry

http://www.rbcsyd.se/

To meet the law requirements and regulations of the National Board of the Southern Health Care Region, Region Skane and Lund University agreed to establish a common biobanking center for Southern healthcare region. Regional biobanksrcentrum will develop and maintain systems for quality assurance and integrity protected using biobanks. The Regional Biobank center is responsible for matters relating to the collection, storage and use of samples stored in biobanks in the Southern healthcare region. Regional Biobank center operations consist of: * to promote the use of biobank material is in accordance with legal requirements biobank * to promote integrity protected and safe storage of repository material * to provide information about the biobank law and biobank materials used for individual sample donors, health professionals, researchers and the public * to handle requests for modified consent and desire to destroy or de test * maintaining a current and privacy protected records of repository material in the region * work to the individual''s integrity will be strengthened in relation to research on biobank material. Tissue samples available to other parties, by surrendering, or by sending tissue samples for analysis, requiring the return or destruction, after completion of the analysis. Regional Biobank Centre (RBC) for the southern healthcare region was established in 2004 and was until 2010 in the Oncology Centre. As of January 1, 2011 it is under the management of RBC Labmedicin Skane.

Proper citation: Swedish Regional Biobank (RRID:SCR_004503) Copy   

•   Source: SciCrunch Registry

http://www.tmf-ev.de/BiobankenRegisterEN/Registry.aspx?udt_2021_param_detail=72

It is the aim of the SepNet initiative to establish a central facility, essential to data and sample quality and homogeneity, that comprises a structured and easily accessible sample bank with probes of homogeneous quality originating from a well-characterized patient population enrolled in independent, innovative and internationally competitive prospective clinical sepsis trials. The SepNetBiobank is a core facility of SepNet. The object of this central sample resource is to organize and handle all relevant aspects of sampling, storage and delivery of samples in the SepNet collaboration to ensure homogeneity of the samples in terms of specimen quality and maintaining sampling standards. This will be achieved through central handling of samples collected in peripheral nationwide 17 regional centers and an additional 36 associated centers according to an agreed sampling scheme and pre-set standards for sample quality, sample handling and banking; quality assurance and all relevant parts of sample handling will be in the hands of the core unit, minimizing pre-analytical steps in the heterogeneous environment of the different regional centers. In the next few months a fully automated sample storage system will be implemented that allows handling of more than 200.000 individual aliquots expected after completion of the different ongoing and planned SepNet Trails. In the next six months a fully automated -80 degree C sample storage system will be implemented. After completion of the plannend and ongoing SepNet trials more than 59.710 expected primary samples (218.040 aliquots) will be stored in this system. This outstanding sample resource will provide the basis for scientific projects aming at improving patient care with sepsis e.g. advancement in diagnostics, risk stratification, therapy and outcome.

Proper citation: SepNet Central Sample Bank (RRID:SCR_004543) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/AREDS/?SsId=68

The NEI-AREDS Genetic Repository is a collection of genetic material submitted by participants in the Age-Related Eye Disease Study (AREDS) which was sponsored by the National Eye Institute (NEI). The Repository stores DNA for use by investigators conducting genetics research into the causes of eye disease. The Age-Related Eye Disease Study was designed to learn about macular degeneration and cataract, two leading causes of vision loss in older adults. The study looked at how these two diseases progress and what their causes may be. In addition, the study tested certain vitamins and minerals to find out if they can help to prevent or slow these diseases. Participants in the study did not have to have either disease. (Enrollment was completed in January 1998.) Eleven medical centers in the United States took part in the study, and more than 4,700 people across the country were enrolled in AREDS. The study was supported by the National Eye Institute, part of the Federal government''s National Institutes of Health. The clinical trial portion of the study also received support from Bausch & Lomb Pharmaceuticals and was completed in October 2001. Data from AREDS is publicly available in the Database of Genotypes and Phenotypes (dbGaP). Genetic samples from 600 AREDS participants (200 controls, 200 Neovascular AMD cases, and 200 Geographic Atrophy cases) were selected using data available in March 2005 and then were genotyped using the Illumina 100K and the Affymetrix 100K gene chips. These genotype data are available in the dbGaP. DNA samples are distributed only to qualified professional persons who are associated with recognized research, medical, educational, or industrial organizations engaged in health-related research or health delivery. All orders for DNA samples must be submitted using the online catalog.

Proper citation: NEI-AREDS Genetic Repository (RRID:SCR_004536) Copy   

•   Source: SciCrunch Registry

http://www.seqwright.com/clinicaltrialservices/biorepository.html

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. A pilot effort that has developed a centralized, web-based biospecimen locator that presents biospecimens collected and stored at participating Arizona hospitals and biospecimen banks, which are available for acquisition and use by researchers. Researchers may use this site to browse, search and request biospecimens to use in qualified studies. The development of the ABL was guided by the Arizona Biospecimen Consortium (ABC), a consortium of hospitals and medical centers in the Phoenix area, and is now being piloted by this Consortium under the direction of ABRC. You may browse by type (cells, fluid, molecular, tissue) or disease. Common data elements decided by the ABC Standards Committee, based on data elements on the National Cancer Institute''s (NCI''s) Common Biorepository Model (CBM), are displayed. These describe the minimum set of data elements that the NCI determined were most important for a researcher to see about a biospecimen. The ABL currently does not display information on whether or not clinical data is available to accompany the biospecimens. However, a requester has the ability to solicit clinical data in the request. Once a request is approved, the biospecimen provider will contact the requester to discuss the request (and the requester''s questions) before finalizing the invoice and shipment. The ABL is available to the public to browse. In order to request biospecimens from the ABL, the researcher will be required to submit the requested required information. Upon submission of the information, shipment of the requested biospecimen(s) will be dependent on the scientific and institutional review approval. Account required. Registration is open to everyone., documented on August 17, 2021.Convenient, cost-effective and reliable storage solutions including maintaining, storing and monitoring your biological samples. Avoid costly purchases of ultra-low temperature freezers, sample tracking LIMS, and layers of emergency back-up infrastructure. Enjoy peace of mind in the knowledge that your critical samples are safe, secure, and readily available to you. Service Features * Real-time sample tracking and monitoring, with 24/7 accessibility. * GLP compliant repository with cold chain of custody. * Numerous storage options, from ambient temperature to -170 degrees C. * Hazardous specimen storage capabilities. * Redundant emergency back-up systems. * Secure-access facility. * At Temperature back-up freezers. * Rapid domestic & international shipping. As a full-service contract genomics provider, SeqWright is able to offer our BioRepository customers the additional benefit of a broad portfolio of regulated services for testing of samples, as and when required, and then returning the samples back to our BioRepository for further storage. Contact us for your customized solution.

Proper citation: SeqWright Biorepository (RRID:SCR_004657) Copy   

•   Source: SciCrunch Registry

http://www.seracare.com/OurProductsandServices/SampleStorageManagementandProcessing/tabid/159/Default.aspx

SeraCare stores and manages over 19 million samples in our state-of-the-art biobank, and is supported by a range of processing and characterization services. Security. Backup. On-line inventory. Next day sample access. Analysis. Characterization. Anonymization. Transformation. Restoration. Compliance. Coordination. We handle your samples all the way through. SeraCare is well-equipped to perform a wide range of sample storage, management, and processing services. We have longstanding customer relationships with clinical and research laboratories, biopharma, and public health agencies, including the National Institutes of Health, the Centers for Disease Control, and the US Food and Drug Administration. * Our scientists have expertise in virology, immunology, molecular biology, and biochemistry * We have a proven legacy of custom assay design and custom product development to meet your specifications

Proper citation: SeraCare Lifesciences: Sample Storage Management and Processing Services (RRID:SCR_004535) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/the-imse-studies-imse-i-and-imse-ii

Immunomodulatory drugs in multiple sclerosis (IMSE) is a nation-wide pharmacoepidemiological and genetic study on persons treated with Tysabri. The study focuses on response to treatment and development of neutralizing antibodies, and to perform large-scale genetic studies. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 1293 (June 2010)

Proper citation: KI Biobank - IMSE (RRID:SCR_005899) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29354&a=31616&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. The study Genetic Regulation of the End-Stage Clotting Process that leads to Thrombotic Stroke (EuroClot) aims specifically to identify the major genes involved in variations of the end-stage clotting process and investigate the role of these novel genes (and existing candidate genes) in the pathogenesis of stroke across Europe. EuroClot will study stroke intermediate phenotypes in 4500 twins from GenomEUtwin project involving 8 countries and 1000 subjects from extended families from the GAIT2 (Spain) and EuroHead (Finland) studies. Types of samples * EDTA whole blood * DNA * Plasma * Serum Number of sample donors: 601 (sample collection completed)

Proper citation: KI Biobank - EuroClot (RRID:SCR_005932) Copy   

•   Source: SciCrunch Registry

http://ki.se/meb/stanley-studien

This study will include 5000 individuals recruited from The National Quality Register for Bipolar Disorder (Bipol��R) and The National Patient Register (Patientregistret) from which subjects with two or more hospitalizations with bipolar disorder will be eligible for inclusion. Bipolar disorder (manodepressive illness) is an often devastating neuropsychiatric disorder associated with considerable morbidity, mortality, human suffering, and societal costs. Genetic epidemiological studies provide indirect evidence of the importance of inheritance as bipolar disorder is clearly familial. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 915 (June 2010)

Proper citation: KI Biobank - STANLEY (RRID:SCR_005922) Copy   

•   Source: SciCrunch Registry

http://ki.se/meb/star

Large, ongoing, multifactorial study based on nation-wide ascertainment of patients with schizophrenia and bipolar disorder through the Swedish Twin Registry to include both neuroimaging data, neurocognitive function, molecular genetic data and early adverse environmental factors in the same model in a genetic sensitive design. Swedish schizophrenia research will benefit from this large study database of in total 240 affected and healthy twin pairs collected over a 5 year period. The specific aims are: * To elucidate neural endophenotypes for schizophrenia and bipolar disorder and to clarify the extent of overlap in these features between the two syndromes. * To investigate candidate genes and genomic regions for linkage and association with neural endophenotypes for schizophrenia and bipolar disease. * To determine the contributions of adverse prenatal and perinatal conditions to neural changes associated with schizophrenia and bipolar disease. Types of samples * EDTA whole blood * DNA * RNA Number of sample donors: 251 (June 2010)

Proper citation: KI Biobank - STAR (RRID:SCR_005923) Copy   

•   Source: SciCrunch Registry

http://www.kreftregisteret.no/en/Research/Janus-Serum-Bank/

The Janus Serum Bank has blood samles from 317 000 Norwegians. The biobank is reserved for cancer research, and is internationally unique regarding size and number of cancer cases. The Janus Serum Bank is a population based biobank reserved for cancer research. The specimens are collected during the period from 1972-2004 and are stored at 25 degrees Celsius. The samples originate from 317 000 persons in Norway who have participated in health studies and also from blood donors in and around Oslo. Today, samples are only collected from earlier donors in the Janus Serum Bank who have developed cancer. The Bank is internationally unique regarding size and number of cancer cases. Annual linkage to the Cancer Registry shows that 52 500 donors are diagnosed with cancer as of December 31, 2009. The main goals of the biobank are to make the material available to cancer researchers over the whole world and deliver quality assured samples and data. The Janus Serum Bank is registered in the Biobank Register (Notification number 737)

Proper citation: Janus Serum Bank (RRID:SCR_005885) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/cns/mikael-landen-research-group

THIS RESOURCE IS NO LONGER IN SERVICE, documented on January 19,2022. The St G??ran Bipolar Study (SBP) is a prospective naturalistic study of patients suffering from bipolar disorder. Consenting patients are enrolled when diagnosed with any of Bipolar I, II, NOS disorder, cyclothymia, or schizoaffective disorder. At baseline, medical and social history is meticulously reviewed and the clinical diagnosis is established using a structured diagnostic instrument. Types of samples * EDTA whole blood * DNA * Plasma * Serum * Cerebrospinal fluid Number of sample donors: 371 (June 2010)

Proper citation: KI Biobank - SBP (RRID:SCR_005920) Copy   

•   Source: SciCrunch Registry

http://www.kcl.ac.uk/medicine/research/divisions/diiid/centres/pii/biobank/index.aspx

Centralized specimen archiving and molecular analysis facility that assists researchers wishing to undertake cohort-based projects in areas such HIV/AIDS, HCV infection or MRSA. Its aim is to make medical research easier, more efficient and faster to perform. The IDB collects valuable clinical samples from patients with infections who are attending their partner NHS-Trust clinics. Their core collections include blood samples from patients infected with human immunodeficiency virus (HIV), hepatitis B (HBV) & hepatitis C (HCV) viruses or methicillin resistant Staphylococcus aureus (MRSA). Blood samples are separated so that patients������?? DNA, plasmas (cell-free blood) and lymphocytes (white blood cells) can be frozen into a comprehensive library. Medical researchers can access complete sets of samples to answer important clinical questions, if their research project is approved by the IDB''s Management Committee. For this reason they are actively recruiting ''medically interesting'' patients who are infected with HIV, for example: those who remain well ������?? despite being infected for many years; others who are exposed to HIV but remain uninfected; others who develop AIDS very quickly; and, those who are in the process of sero-converting.

Proper citation: Kings College London Infectious Diseases BioBank (RRID:SCR_004827) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/broad

The study will collect 1,500 cases with schizophrenia and 1,500 well-matched controls ascertained via high-quality Swedish national hospitalization and population registries. Both cases and controls will be population-based and of Scandinavian ancestry. Types of samples * EDTA whole blood * DNA Number of donors: 10 820 (June 2010)

Proper citation: KI Biobank - BROAD (RRID:SCR_005916) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/twingene-and-genomeeutwin

In collaboration with GenomeEUtwin, the TwinGene project investigates the importance of quantitative trait loci and environmental factors for cardiovascular disease. It is well known that genetic factors are of considerable importance for some familial lipid syndromes and that Type A Behavior pattern and increased lipid levels infer increased risk for cardiovascular disease. It is furthermore known that genetic factors are of importance levels of blood lipid biomarkers. The interplay of genetic and environmental effects for these risk factors in a normal population is less well understood and virtually unknown for the elderly. In the TwinGene project twins born before 1958 are contacted to participate. Health and medication data are collected from self-reported questionnaires, and blood sampling material is mailed to the subject who then contacts a local health care center for blood sampling and a health check-up. In the simple health check-up, height, weight, circumference of waist and hip, and blood pressure are measured. Blood is sampled for DNA extraction, serum collection and clinical chemistry tests of C-reactive protein, total cholesterol, triglycerides, HDL and LDL cholesterol, apolipo��protein A1 and B, glucose and HbA1C. The TwinGene cohort contains more than 10000 of the expected final number of 16000 individuals. Molecular genetic techniques are being used to identify Quantitative Trait Loci (QTLs) for cardiovascular disease and biomarkers in the TwinGene participants. Genome-wide linkage and association studies are ongoing. DZ twins have been genome-scanned with 1000 STS markers and a subset of 300 MZ twins have been genome-scanned with Illumina 317K SNP platform. Association of positional candidate SNPs arising from these genomscans are planned. The TwinGene project is associated with the large European collaboration denoted GenomEUtwin (www.genomeutwin.org, see below) which since 2002 has aimed at gathering genetic data on twins in Europe and setting up the infrastructure needed to enable pooling of data and joint analyses. It has been the funding source for obtaining the genome scan data. Types of samples: * EDTA whole blood * DNA * Serum Number of sample donors: 12 044 (sample collection completed)

Proper citation: KI Biobank - TwinGene (RRID:SCR_006006) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29328&a=30572&l=en

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016.

Proper citation: KI Biobank - NOAK (RRID:SCR_006008) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29354&a=103615&l=en

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. The SALTY study will contact approximately 25 000 twins born 1943 - 1958. One of the main purposes with the study is to continue to build up the Swedish Twin Biobank which was established by the Twin Gene project.

Proper citation: KI Biobank - SALTY (RRID:SCR_006003) Copy   

•   Source: SciCrunch Registry

http://www.cryolife.com

A biological medical device company that focuses on the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac and vascular for patients of all ages. The Company''s research and development efforts are focused on Protein Hydrogel Technologies, such as BioFoam Surgical Matrix for parenchymal organ sealing. The Company is also investigating additional applications for its SynerGraft decellularization technology. CryoLife provides surgeons with multiple tissue options for cardiovascular reconstruction. CryoLife preserved allografts have helped save the lives and limbs of patients for 20 years. CryoLife''s tissue, along with BioGlue and BioFoam offer a wide range of Life Restoring Technologies for cardiac and vascular surgeons. CryoLife provides innovative products that will benefit patients around the world by working with other pioneering companies and by continuous investment in research and development.

Proper citation: CryoLife, Inc. (RRID:SCR_005037) Copy   

•   Source: SciCrunch Registry